tetano
Editor, Senior Moderator
J Med Virol
. 2023 Aug;95(8):e29031.
doi: 10.1002/jmv.29031. Omicron breakthrough infections in wild-type SARS-CoV-2 vaccinees elicit high levels of neutralizing antibodies against pangolin coronavirus GX_P2V
Shanshan Lu[SUP] 1 [/SUP], Shengdong Luo[SUP] 2 [/SUP], Bingke Bai[SUP] 2 [/SUP], Zhenping Fan[SUP] 2 [/SUP], Bixia Hong[SUP] 1 [/SUP], Wen Xu[SUP] 2 [/SUP], Hongbin Ma[SUP] 2 [/SUP], Weiwei Chen[SUP] 2 [/SUP], Huahao Fan[SUP] 1 [/SUP], Yigang Tong[SUP] 1 [/SUP], Lihua Song[SUP] 1 [/SUP]
Affiliations
Omicron BF.7 became the predominant SARS-CoV-2 variant in Beijing after the abolishment of Zero-COVID policy in December 2022. The ability of antibodies elicited by BF.7 infection to cross-react with SARS-CoV-2-like viruses is unknown. This study aimed to investigate the cross-reactive neutralizing antibodies against SARS-CoV-2-related pangolin coronavirus GX_P2V in sera from vaccinated and/or SARS-CoV-2-infected individuals. All vaccinated individuals who recovered from Omicron BF.7 breakthrough infections exhibited substantially higher levels of neutralizing antibodies against GX_P2V, compared to other subject groups, with a geometric mean titer (GMT) of 362. Uninfected individuals who received four-mixed-dose vaccines also demonstrated higher levels of neutralizing antibodies (GMT = 44) against GX_P2V than those uninfected individuals who received two- or three-dose vaccines and those unvaccinated convalescents of wild-type SARS-CoV-2. This study highlights the significance of prior vaccinations with wild-type SARS-CoV-2 vaccines in generating potent cross-protective immunity against future spillovers of SARS-CoV-2-like viruses.
Keywords: COVID-19; Omicron BF.7; cross-protective immunity; pangolin coronavirus GX_P2V.
. 2023 Aug;95(8):e29031.
doi: 10.1002/jmv.29031. Omicron breakthrough infections in wild-type SARS-CoV-2 vaccinees elicit high levels of neutralizing antibodies against pangolin coronavirus GX_P2V
Shanshan Lu[SUP] 1 [/SUP], Shengdong Luo[SUP] 2 [/SUP], Bingke Bai[SUP] 2 [/SUP], Zhenping Fan[SUP] 2 [/SUP], Bixia Hong[SUP] 1 [/SUP], Wen Xu[SUP] 2 [/SUP], Hongbin Ma[SUP] 2 [/SUP], Weiwei Chen[SUP] 2 [/SUP], Huahao Fan[SUP] 1 [/SUP], Yigang Tong[SUP] 1 [/SUP], Lihua Song[SUP] 1 [/SUP]
Affiliations
- PMID: 37561639
- DOI: 10.1002/jmv.29031
Omicron BF.7 became the predominant SARS-CoV-2 variant in Beijing after the abolishment of Zero-COVID policy in December 2022. The ability of antibodies elicited by BF.7 infection to cross-react with SARS-CoV-2-like viruses is unknown. This study aimed to investigate the cross-reactive neutralizing antibodies against SARS-CoV-2-related pangolin coronavirus GX_P2V in sera from vaccinated and/or SARS-CoV-2-infected individuals. All vaccinated individuals who recovered from Omicron BF.7 breakthrough infections exhibited substantially higher levels of neutralizing antibodies against GX_P2V, compared to other subject groups, with a geometric mean titer (GMT) of 362. Uninfected individuals who received four-mixed-dose vaccines also demonstrated higher levels of neutralizing antibodies (GMT = 44) against GX_P2V than those uninfected individuals who received two- or three-dose vaccines and those unvaccinated convalescents of wild-type SARS-CoV-2. This study highlights the significance of prior vaccinations with wild-type SARS-CoV-2 vaccines in generating potent cross-protective immunity against future spillovers of SARS-CoV-2-like viruses.
Keywords: COVID-19; Omicron BF.7; cross-protective immunity; pangolin coronavirus GX_P2V.